Biotechnology
Upcoming Earnings
Cancer Prevention
Sorrento Therapeutics
$5.259876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$5.25
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.57 (-9.60%) Today
-$0.12 (-2.23%) After Hours
Why Robinhood?
You can buy or sell SRNE and other stocks, options, ETFs, and crypto commission-free!
About
Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. Read More The company was founded by Henry H. Ji in 2006 and is headquartered in San Diego, CA.
CEO
Employees
382
Headquarters
San Diego, California
Founded
2006
Market Cap
726.34M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
2.08M
High Today
$5.71
Low Today
$4.90
Open Price
$5.40
Volume
3.08M
52 Week High
$8.25
52 Week Low
$1.80
Collections
Biotechnology
Upcoming Earnings
Cancer Prevention
Biopharmaceutical
Top Movers
Therapy
Research And Development
Health
News
InvestorPlaceMar 22
Sorrento Therapeutics News: Why SRNE Stock Is On The Move
Recent Sorrento Therapeutics news has SRNE stock on a roller coaster ride today. Source: Shutterstock Sorrento Therapeutics (NASDAQ: SRNE ) announced today that its majority owned subsidiary Scilex Pharmaceuticals is merging with Semnur Pharmaceuticals. This merger has the two companies coming together in an effort to create a leader in the non-opioid pain medicine market. The new company’s name is Scilex Holding Company The Sorrento Therapeutics news means that the company’s stake in Scilex Pharmaceutic...
Markets InsiderMar 22
Sorrento Therapeutics Announces the Merger of Scilex and Semnur to Create a Global Leader in Non-Opioid Pain Management
Semnur’s SP102, addressing multi-billion dollar unmet market needs, in Pivotal Phase 3 Trial with Fast Track Status from the FDA With non-opioid ZTlido, RTX, and SP102 commercial and near-commercial product lines, Sorrento and its subsidiaries are addressing $63 billion market in pain management (1) SAN DIEGO, March 22, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE) announced today that its majority owned subsidiary Scilex Pharmaceuticals Inc. (Scilex) has closed a transaction to me...
Associated PressMar 11
CORRECTING and REPLACING - Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. SEOUL, South Korea and SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Sorrento Therapeutics, Inc. (Nasdaq: SRNE), please note that in the subheadline the year the Pha...
Price Paid on Robinhood
1% Higher
Right Now
52 Week Low
$1.80
Average Price Paid
$5.19
52 Week High
$8.25
Earnings
-$0.73
-$0.34
$0.05
$0.44
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.29 per share
Actual
Expected Mar 27, Pre-Market